The entirety of human leukocyte antigen (HLA)‐presented peptides is referred to as the HLA
ligandome of a cell or tissue, in tumours often termed immunopeptidome. Mapping the …

Regulation of transcription, replication, and cell division relies on differential protein binding
to DNA and chromatin, yet it is unclear which regulatory components remain bound to …

Background Glioblastoma (GBM) is the most common and malignant primary brain tumor in
adults. Despite maximal treatment, median survival remains dismal at 14–24 months …

Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to
most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose …

Recent studies have shown that the noncoding genome can produce unannotated proteins
as antigens that induce immune response. One major source of this activity is the aberrant …

One of the challenges for cancer vaccine and adoptive T-cell-based immunotherapy is to
identify the major histocompatibility complex (MHC)-associated non-self neoantigens …

According to the 2020 Metrics of the HUPO Human Proteome Project (HPP), expression has
now been detected at the protein level for> 90% of the 19 773 predicted proteins coded in …

The immunopeptidome is the repertoire of peptides bound and presented by the MHC class
I, class II, and non-classical molecules. The peptides are produced by the degradation of …

Due to their delicate locations as well as aggressive and infiltrative behavior, malignant
brain tumors remain a therapeutic challenge. Harnessing the efficacy and specificity of the T …

Precision Neoantigen Discovery Using Large-scale Immunopeptidomes and Composite
Modeling of MHC Peptide Presentation Page 1 Precision Neoantigen Discovery Using …